<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: necessary funds", fill: "#c74375"},
{source: "1: necessary funds", target: "1: operations", fill: "#c74375"},
{source: "1: operations", target: "1: technology position", fill: "#c74375"},
{source: "1: technology position", target: "1: commercialize", fill: "#c74375"},
{source: "1: commercialize", target: "1: therapeutic proteins", fill: "#c74375"},
{source: "1: necessary funds", target: "3: operations", fill: "#059033"},
{source: "3: operations", target: "3: lesser extent from proceeds from property", fill: "#059033"},
{source: "3: lesser extent from proceeds from property", target: "3: investments", fill: "#059033"},
{source: "3: investments", target: "3: collaborations", fill: "#059033"},
{source: "3: collaborations", target: "3: gains from", fill: "#059033"},
{source: "3: operations", target: "4: existing cash", fill: "#c40233"},
{source: "4: existing cash", target: "4: cash equivalents", fill: "#c40233"},
{source: "4: cash equivalents", target: "4: equivalents", fill: "#c40233"},
{source: "4: equivalents", target: "4: revenue from collaborations", fill: "#c40233"},
{source: "4: revenue from collaborations", target: "4: license arrangements", fill: "#c40233"},
{source: "4: license arrangements", target: "4: interest income should", fill: "#c40233"},
{source: "4: interest income should", target: "4: collaborative relationships", fill: "#c40233"},
{source: "4: existing cash", target: "5: future capital requirements depend on", fill: "#3d0c02"},
{source: "5: future capital requirements depend on", target: "5: development", fill: "#3d0c02"},
{source: "5: development", target: "5: technology position", fill: "#3d0c02"},
{source: "5: technology position", target: "5: procuring proteins", fill: "#3d0c02"},
{source: "5: procuring proteins", target: "5: at commercial scale", fill: "#3d0c02"},
{source: "5: at commercial scale", target: "5: clinical testing which", fill: "#3d0c02"},
{source: "5: clinical testing which", target: "5: drug development", fill: "#3d0c02"},
{source: "5: drug development", target: "5: product candidate development", fill: "#3d0c02"},
{source: "5: product candidate development", target: "5: difficulties", fill: "#3d0c02"},
{source: "5: difficulties", target: "5: manufacturing preclinical activities", fill: "#3d0c02"},
{source: "5: manufacturing preclinical activities", target: "5: clinical studies", fill: "#3d0c02"},
{source: "5: clinical studies", target: "5: commercialization", fill: "#3d0c02"},
{source: "5: commercialization", target: "5: willingness", fill: "#3d0c02"},
{source: "5: willingness", target: "5: enter into new agreements with", fill: "#3d0c02"},
{source: "5: enter into new agreements with", target: "5: agreements", fill: "#3d0c02"},
{source: "5: agreements", target: "5: collaborators", fill: "#3d0c02"},
{source: "5: collaborators", target: "5: existing collaborations", fill: "#3d0c02"},
{source: "5: existing collaborations", target: "5: success rate", fill: "#3d0c02"},
{source: "5: success rate", target: "5: clinical efforts associated with milestones", fill: "#3d0c02"},
{source: "5: clinical efforts associated with milestones", target: "5: investigating patents", fill: "#3d0c02"},
{source: "5: investigating patents", target: "5: might block us from", fill: "#3d0c02"},
{source: "5: might block us from", target: "5: potential drug candidates", fill: "#3d0c02"},
{source: "5: potential drug candidates", target: "5: qualified personnel", fill: "#3d0c02"},
{source: "5: qualified personnel", target: "5: costs involved", fill: "#3d0c02"},
{source: "5: costs involved", target: "5: regulatory approvals", fill: "#3d0c02"},
{source: "5: regulatory approvals", target: "5: timing willingness", fill: "#3d0c02"},
{source: "5: timing willingness", target: "5: commercialize products incorporating", fill: "#3d0c02"},
{source: "5: commercialize products incorporating", target: "5: technologies", fill: "#3d0c02"},
{source: "5: technologies", target: "5: filing prosecuting defending", fill: "#3d0c02"},
{source: "5: filing prosecuting defending", target: "5: enforcing patent", fill: "#3d0c02"},
{source: "5: enforcing patent", target: "5: intellectual property rights", fill: "#3d0c02"},
{source: "5: intellectual property rights", target: "5: license complementary technologies", fill: "#3d0c02"},
{source: "5: license complementary technologies", target: "5: new drug targets", fill: "#3d0c02"},
{source: "5: new drug targets", target: "5: competitive landscape", fill: "#3d0c02"},
{source: "5: future capital requirements depend on", target: "59: from studies", fill: "#b19cd9"},
{source: "59: from studies", target: "59: clinical trials could", fill: "#b19cd9"},
{source: "59: clinical trials could", target: "59: regulatory agencies", fill: "#b19cd9"},
{source: "59: from studies", target: "75: product development", fill: "#95b"},
{source: "75: product development", target: "75: commercial manufacturing", fill: "#95b"},
{source: "75: commercial manufacturing", target: "75: face challenges unique", fill: "#95b"},
{source: "75: product development", target: "77: third parties with whom", fill: "#fbceb1"},
{source: "77: third parties with whom", target: "77: manufacture", fill: "#fbceb1"},
{source: "77: manufacture", target: "77: manufacturing proteins", fill: "#fbceb1"},
{source: "77: manufacturing proteins", target: "77: difficult", fill: "#fbceb1"},
{source: "77: difficult", target: "77: up protein manufacturing processes", fill: "#fbceb1"},
{source: "77: third parties with whom", target: "START_HERE", fill: "#fbceb1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/L3Harris_Technologies">L3Harris Technologies</a></td>
      <td>L3Harris Technologies (L3Harris) is an American technology company, defense contractor, and information technology services provider that produces C6ISR systems and products, wireless equipment, tactical radios, avionics and electronic systems, night vision equipment, and both terrestrial and spaceborne antennas for use in the government, defense, and commercial sectors. They specialize in surveillance solutions, microwave weaponry, and electronic warfare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NEOSE TECHNOLOGIES INC      ITEM 1A <font color="blue">RISK FACTORS </font>                                 Financial Risks       If we fail to obtain <font color="blue"><font color="blue">necessary</font> funds</font> for our <font color="blue">operations</font>, we will be unable     to maintain and improve our <font color="blue"><font color="blue">technology</font> position</font> and we will be unable to     develop and <font color="blue">commercialize</font> our <font color="blue"><font color="blue">therapeutic</font> proteins</font></td>
    </tr>
    <tr>
      <td>To date, we have funded our <font color="blue">operations</font> primarily through proceeds     from the public and <font color="blue">private placements</font> of <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We have also     funded our <font color="blue">operations</font> to a <font color="blue">lesser extent from proceeds from property</font> and     equipment financing, interest earned on <font color="blue"><font color="blue">investment</font>s</font>, revenues from corporate     <font color="blue"><font color="blue">collaboration</font>s</font> and <font color="blue">gains from</font> the sale of <font color="blue"><font color="blue">investment</font>s</font></td>
    </tr>
    <tr>
      <td>We believe that our     <font color="blue">existing cash</font> and <font color="blue">cash <font color="blue">equivalents</font></font>, expected revenue from <font color="blue"><font color="blue">collaboration</font>s</font> and     <font color="blue">license arrangements</font>, and <font color="blue">interest income should</font> be sufficient to meet our     operating and capital <font color="blue">requirements</font> at least through 2006, although changes     in our <font color="blue"><font color="blue">collaborative</font> relationships</font> or our business, whether or not initiated     by  us,  may  affect  the  rate  at which we deplete our cash and cash     <font color="blue">equivalents</font></td>
    </tr>
    <tr>
      <td>Our present and <font color="blue">future capital <font color="blue">requirements</font> depend on</font> many     factors, including:       •   level of research and <font color="blue">development</font> <font color="blue">investment</font> required to develop our     <font color="blue"><font color="blue">therapeutic</font> proteins</font>, and maintain and improve our <font color="blue"><font color="blue">technology</font> position</font>;          •     the costs of <font color="blue">procuring proteins</font> and reagents for research and     <font color="blue">development</font> and <font color="blue">at <font color="blue">commercial scale</font></font>;          •     the results of preclinical and clinical testing, which can be     unpredictable in drug <font color="blue">development</font>;         •   changes in <font color="blue">product candidate</font> <font color="blue">development</font> plans needed to address any     <font color="blue"><font color="blue">difficult</font>ies</font>  that may arise in <font color="blue">manufacturing</font>, preclinical <font color="blue">activities</font>,     <font color="blue">clinical studies</font> or <font color="blue">commercialization</font>;          •     our ability and <font color="blue">willingness</font> to <font color="blue">enter into new <font color="blue"><font color="blue">agreement</font>s</font> with</font>     <font color="blue"><font color="blue">collaborator</font>s</font> and to extend or maintain our existing <font color="blue"><font color="blue">collaboration</font>s</font>, and the     terms of these <font color="blue"><font color="blue">agreement</font>s</font>;         •   our <font color="blue">success rate</font> and that of our <font color="blue"><font color="blue">collaborator</font>s</font> in preclinical and     <font color="blue">clinical efforts associated with milestones</font> and royalties;         •   the costs of <font color="blue"><font color="blue">investigating</font> patents</font> that <font color="blue">might block us from</font> developing     <font color="blue">potential <font color="blue">drug <font color="blue">candidates</font></font></font>;         •   the costs of recruiting and retaining <font color="blue">qualified personnel</font>;         •   the time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;          •     the  timing, <font color="blue">willingness</font>, and ability of our <font color="blue"><font color="blue">collaborator</font>s</font> to     <font color="blue">commercialize</font> products <font color="blue">incorporating</font> our <font color="blue">technologies</font>;         •   the costs of filing, prosecuting, defending, and <font color="blue">enforcing patent</font>     claims and other <font color="blue"><font color="blue">intellectual</font> property rights</font>;         •   our need or decision to acquire or license complementary <font color="blue">technologies</font>     or <font color="blue">new drug targets</font>; and         •   the evolution of the <font color="blue">competitive landscape</font></td>
    </tr>
    <tr>
      <td>-11-       _________________________________________________________________                     We will require <font color="blue"><font color="blue">significant</font> amounts</font> of <font color="blue"><font color="blue">additional</font> capital</font> in the     future, and we do not have any assurance that <font color="blue">funding will</font> be available when     we need it on terms that we find favorable, if at all</td>
    </tr>
    <tr>
      <td>We may seek to raise     these <font color="blue">funds through public</font> or private equity offerings, debt financings,     credit <font color="blue">facilities</font>, or corporate <font color="blue"><font color="blue">collaboration</font>s</font> and <font color="blue">licensing arrangements</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> capital</font> by issuing <font color="blue">equity securities</font>, our     existing stockholders’ percentage ownership will be reduced and they may     experience substantial dilution</td>
    </tr>
    <tr>
      <td>We may also issue <font color="blue">equity securities</font> that     provide for rights, preference and <font color="blue">privileges senior</font> to those of our common     stock</td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">raise <font color="blue"><font color="blue">additional</font> funds</font></font> by issuing debt securities</font>, these debt     <font color="blue">securities would</font> have rights, preferences, and <font color="blue">privileges senior</font> to those of     our <font color="blue">common stock</font>, and the terms of the <font color="blue">debt securities issued could impose</font>     <font color="blue"><font color="blue">significant</font> restrictions on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise <font color="blue"><font color="blue">additional</font> funds</font></font>     through <font color="blue"><font color="blue">collaboration</font>s</font> and <font color="blue">licensing arrangements</font>, we may be required to     <font color="blue">relinquish</font> some rights to our <font color="blue">technologies</font> or <font color="blue">drug <font color="blue">candidates</font></font>, or to grant     <font color="blue">licenses on terms</font> that are not favorable to us</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not     available or are not <font color="blue">available on</font> acceptable terms, our ability to fund our     <font color="blue">operations</font>,  take  advantage  of  <font color="blue">opportunities</font>,  develop products and     <font color="blue">technologies</font>,  and otherwise respond to <font color="blue">competitive pressures could</font> be     <font color="blue"><font color="blue">significant</font>ly delayed</font> or limited, and we may need to downsize or halt our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">debt <font color="blue">obligations</font></font> include <font color="blue">restrictive covenants which may restrict</font> our     <font color="blue">operations</font> or <font color="blue">otherwise <font color="blue">adversely</font> affect us</font></td>
    </tr>
    <tr>
      <td>We have a credit <font color="blue">facility</font>, which was amended in <font color="blue">February </font>2006,     with a <font color="blue">bank consisting</font> of a credit <font color="blue">agreement</font> and a financing <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>As     of <font color="blue">December </font>31, 2005, the <font color="blue">outstanding balance under</font> the credit <font color="blue">facility</font> was     dlra8dtta1 million</td>
    </tr>
    <tr>
      <td>Pursuant to the <font color="blue"><font color="blue">agreement</font>s</font> comprising the credit <font color="blue">facility</font>, we     agreed to limit our <font color="blue">total outstanding debt</font> to dlra22dtta0 million; therefore, we     <font color="blue">cannot exceed</font> this <font color="blue">limit without</font> the bank’s consent</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31,     2005, our <font color="blue">total outstanding debt</font> was dlra14dtta5 million</td>
    </tr>
    <tr>
      <td>The limit on our total     <font color="blue">debt under</font> the credit <font color="blue">agreement</font> could <font color="blue">adversely</font> affect us by reducing our     <font color="blue">flexibility</font> in planning for, or reacting to, changes in our business and our     industry</td>
    </tr>
    <tr>
      <td>If the bank determines a material adverse change has occurred in     our  business, financial condition, results of <font color="blue">operations</font>, or business     prospects, the bank, in its sole <font color="blue">discretion</font>, may declare at any time an     event of default, of which one potential outcome could be the <font color="blue">accelerated</font>     repayment of the <font color="blue">then outstanding loan balance under</font> the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If we     fail  at  any  time to maintain a minimum required cash and short-term     <font color="blue"><font color="blue">investment</font>s</font> balance of at least dlra12dtta0 million, the bank has the option to     require us to make a payment to reduce the <font color="blue">outstanding balance under</font> the     credit  <font color="blue">facility</font> to dlra6dtta0 million</td>
    </tr>
    <tr>
      <td>If we fail at any time to maintain a     minimum  required  cash and short-term <font color="blue"><font color="blue">investment</font>s</font> balance of at least     dlra10dtta0 million, the bank has the option to require us to make a payment to     reduce the <font color="blue">outstanding balance under</font> the credit <font color="blue">facility</font> to dlra5dtta0 million</td>
    </tr>
    <tr>
      <td>Finally, if we fail at any time to maintain a minimum required cash and     short-term  <font color="blue"><font color="blue">investment</font>s</font>  balance  of  at least dlra5dtta0 million we will be     considered to be in default of the credit <font color="blue">facility</font> and the bank may take     <font color="blue">certain actions</font> in relation to that default, including, but not limited to,     requiring  us to repay the entire <font color="blue">outstanding balance under</font> the credit     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we maintained a cash and <font color="blue">cash <font color="blue">equivalents</font></font>     balance of dlra37dtta7 million</td>
    </tr>
    <tr>
      <td>During 2006, we anticipate <font color="blue">average quarterly</font>     spending of approximately dlra8dtta0 million to dlra8dtta5 million to fund our operating     <font color="blue">activities</font>, capital <font color="blue">expenditures</font>, and debt repayments, without giving effect     to the impact of <font color="blue">entering into</font> any new <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> or disposing     of our <font color="blue">current headquarters</font> and <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We believe that our     <font color="blue">existing cash</font> and <font color="blue">cash <font color="blue">equivalents</font></font>, expected revenue from <font color="blue"><font color="blue">collaboration</font>s</font> and     <font color="blue">license arrangements</font>, and <font color="blue">interest income should</font> be sufficient to meet our     operating and capital <font color="blue">requirements</font> at least through 2006</td>
    </tr>
    <tr>
      <td>Accordingly, we     will need to raise substantial <font color="blue"><font color="blue">additional</font> funds</font> to <font color="blue">avoid violating</font> the debt     <font color="blue">covenant described</font> above (See “Overview” in the Management’s Discussion and     Analysis of Financial Condition and Results of Operations section of this     Form 10-K) and fund our <font color="blue">operations</font> until we are <font color="blue">generating sufficient cash</font>     flow from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue"><font color="blue">agreement</font>s</font>  comprising the credit <font color="blue">facility</font> also contain     covenants that, among other things, require us to obtain <font color="blue">consent from</font> the     <font color="blue">bank prior</font> to <font color="blue">paying dividends</font>, making certain <font color="blue"><font color="blue">investment</font>s</font>, changing the     nature of our business, assuming or <font color="blue">guaranteeing</font> the <font color="blue">indebtedness</font> of another     entity  or individual, selling or <font color="blue">otherwise disposing</font> of a substantial     portion of our assets, or merging or <font color="blue">consolidating with</font> another entity</td>
    </tr>
    <tr>
      <td>A breach of any of the <font color="blue">financial tests</font> or other covenants in the     <font color="blue"><font color="blue">agreement</font>s</font> comprising the credit <font color="blue">facility</font> could result in a <font color="blue">default under</font>     those <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Upon the occurrence of an event of default, the <font color="blue">bank could</font>     elect to declare all <font color="blue">amounts outstanding under</font> the credit <font color="blue">facility</font> to be     <font color="blue">immediately due</font> and payable, and terminate all <font color="blue">commitments</font> to <font color="blue">extend further</font>     credit</td>
    </tr>
    <tr>
      <td>-12-       _________________________________________________________________           We have a history of losses, and we <font color="blue">may incur continued losses</font> for some     time</td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred losses each year</font> of our existence, including net     losses of dlra51dtta8 million for the year ended <font color="blue">December </font>31, 2005, dlra41dtta6 million     for the year ended <font color="blue">December </font>31, 2004, and dlra37dtta7 million for the year ended     <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>Given our planned level of operating expenses, we expect     to <font color="blue">continue incurring losses</font> for some time</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had     an  <font color="blue">accumulated</font>  deficit  of  dlra239dtta2 million</td>
    </tr>
    <tr>
      <td>To date, we have derived     <font color="blue">substantially</font> all of our revenue from corporate <font color="blue"><font color="blue">collaboration</font>s</font>, license     <font color="blue"><font color="blue">agreement</font>s</font>, and <font color="blue"><font color="blue">investment</font>s</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">substantially</font> all of our revenue     for the <font color="blue">foreseeable future will</font> result from these sources and from the     licensing of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We also expect to spend <font color="blue"><font color="blue">significant</font> amounts</font>     to expand our research and <font color="blue">development</font> on our <font color="blue">proprietary</font> <font color="blue">drug <font color="blue">candidates</font></font>     and <font color="blue">technologies</font>, maintain and expand our <font color="blue"><font color="blue">intellectual</font> property position</font>,     and expand our business <font color="blue">development</font> and <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Our level     of operating <font color="blue"><font color="blue">expenditures</font> will vary depending upon</font> the stage of <font color="blue">development</font>     of our <font color="blue"><font color="blue">proprietary</font> proteins</font> and the number and nature of our <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may continue</font> to incur substantial <font color="blue">losses even</font> if our <font color="blue">revenues increase</font></td>
    </tr>
    <tr>
      <td>We have not yet <font color="blue">commercialize</font>d any products or <font color="blue">technologies</font>, and we may     <font color="blue">never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>We have not yet <font color="blue">commercialize</font>d any products or <font color="blue">technologies</font>, and     we may never be able to do so</td>
    </tr>
    <tr>
      <td>Since we began <font color="blue">operations</font> in 1990, we have     not generated any revenues, except from corporate <font color="blue"><font color="blue">collaboration</font>s</font>, license     <font color="blue"><font color="blue">agreement</font>s</font>, and <font color="blue"><font color="blue">investment</font>s</font></td>
    </tr>
    <tr>
      <td>We do not know when or if we will complete any     of our product <font color="blue">development</font> efforts, obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for any     product  <font color="blue">candidates</font>  <font color="blue">incorporating</font>  our  <font color="blue">technologies</font>, or <font color="blue">successfully</font>     <font color="blue">commercialize</font> any <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>Even if we are successful in developing     products that are approved for marketing, we will not be <font color="blue">successful unless</font>     these <font color="blue">products gain <font color="blue">market acceptance</font></font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market acceptance</font> of     these products will depend on a number of factors, including:       •   the timing of <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> in the countries, and for the uses,     we seek;         •   the <font color="blue">competitive environment</font>;         •   the <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the <font color="blue">medical community</font> of the     safety and <font color="blue">clinical efficacy</font> of our products and their <font color="blue">potential advantages</font>     <font color="blue">over existing <font color="blue">therapeutic</font> products</font>;         •   the adequacy and success of distribution, sales and <font color="blue">marketing efforts</font>;     and         •   the pricing and <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and third-party     payors, such as insurance companies, health maintenance <font color="blue">organizations</font> and     other plan <font color="blue">administrators</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, payors or the <font color="blue">medical community</font> in general     may be unwilling to accept, utilize or recommend any of our products or     products <font color="blue">incorporating</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>As a result, we are unable to     predict  the  extent  of future losses or the time required to achieve     <font color="blue">profitability</font>, if at all</td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue"><font color="blue">collaborator</font>s</font> <font color="blue">successfully</font>     develop one or more products that <font color="blue">incorporate</font> our <font color="blue">technologies</font>, we may not     <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Risks Related to Development of Products and Technologies       We may be unable to develop next-generation <font color="blue"><font color="blue">therapeutic</font> proteins</font></td>
    </tr>
    <tr>
      <td>We  are seeking to use our enzymatic <font color="blue">technologies</font> to develop     <font color="blue">proprietary</font> next-generation proteins, generally in <font color="blue"><font color="blue">collaboration</font> with</font> a     partner</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue"><font color="blue">protein drug</font>s involves</font> a range of special     <font color="blue"><font color="blue">challenges</font> at various stages</font> of the process</td>
    </tr>
    <tr>
      <td>In  the preclinical phase of product <font color="blue">development</font>, we and our     partners  will face several potential problems, including producing or     obtaining  supplies  of  the protein on <font color="blue">commercially</font> reasonable terms,     <font color="blue">successfully</font> modifying the protein using our enzymatic <font color="blue">technologies</font>, and     achieving adequate yields of the next-generation protein</td>
    </tr>
    <tr>
      <td>Even if a protein     <font color="blue">development</font> program appears to be <font color="blue">proceeding well</font> in the <font color="blue">early phases</font>, a     <font color="blue">product candidate</font> may fail in <font color="blue"><font color="blue">clinical trial</font>s</font> for several reasons, such as     results indicating that the <font color="blue">product candidate</font> is <font color="blue">less <font color="blue">effective</font> than</font> desired     (eg, the trial failed to meet its <font color="blue">primary objectives</font>) or that it has     harmful or problematic side effects</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">clinical trial</font>s</font> are successful, it     is possible that <font color="blue">problems may</font> arise later during <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>For     example, we are aware that                                        -13-       _________________________________________________________________           <font color="blue">certain marketed</font> EPO products were <font color="blue">associated with pure red cell aplasia</font>     that arose after <font color="blue">marketing <font color="blue">authorization</font></font></td>
    </tr>
    <tr>
      <td>This <font color="blue">highlights</font> the fact that even     after a product is approved for marketing, <font color="blue">problems may</font> arise that can     <font color="blue">negatively affect sales</font> and <font color="blue">increase costs</font></td>
    </tr>
    <tr>
      <td>Our failure to solve any of these <font color="blue">problems could delay</font> or prevent     the <font color="blue">commercialization</font> of products <font color="blue">incorporating</font> our <font color="blue">technologies</font> and could     <font color="blue">negatively impact</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical  </font>and  clinical  trial  results for our products may not be     favorable</td>
    </tr>
    <tr>
      <td>In order to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">commercial sale</font> of     any of our product <font color="blue">candidates</font>, we must conduct both pre<font color="blue">clinical studies</font> and     human <font color="blue"><font color="blue">clinical trial</font>s</font> that <font color="blue">demonstrate</font> the product is safe and <font color="blue">effective</font> for     the use for which we are <font color="blue">seeking approval</font></td>
    </tr>
    <tr>
      <td>Adverse results <font color="blue">from studies</font>,     including <font color="blue"><font color="blue">clinical trial</font>s</font>, could have a negative effect on our ability to     obtain the approval of the FDA or other <font color="blue"><font color="blue">regulatory</font> agencies</font></td>
    </tr>
    <tr>
      <td>We also may not be permitted to undertake or <font color="blue">continue clinical</font>     trials for any of our product <font color="blue">candidates</font> in the future or <font color="blue">may otherwise</font> be     unable to do so because acceptable <font color="blue">candidates</font> to <font color="blue">participate</font> in such trials     are unavailable</td>
    </tr>
    <tr>
      <td>Even if we are able to <font color="blue">conduct such trials</font>, we may not be     able to <font color="blue">demonstrate</font> satisfactorily that the products are safe and <font color="blue">effective</font>     and <font color="blue">thus qualify</font> for the <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> <font color="blue">necessary</font> to <font color="blue">commercialize</font>     them</td>
    </tr>
    <tr>
      <td>Safety and efficacy results from pre<font color="blue">clinical studies</font> involving     animals  and other models and from early <font color="blue"><font color="blue">clinical trial</font>s</font> are often not     accurate <font color="blue">indicators</font> of results of later-stage <font color="blue"><font color="blue">clinical trial</font>s</font> that involve     <font color="blue">larger human populations</font>, and, moreover, may not always be <font color="blue">representative</font> of     results obtained <font color="blue">while marketing</font> an approved drug, particularly with regard     to safety</td>
    </tr>
    <tr>
      <td>Proteins are <font color="blue">uniquely susceptible</font> to <font color="blue"><font color="blue">neutralizing</font> <font color="blue">antibodies</font></font> that could     result in <font color="blue">diminished efficacy</font> of our products</td>
    </tr>
    <tr>
      <td>Proteins that are foreign to a living body <font color="blue">often provoke</font> an immune     response</td>
    </tr>
    <tr>
      <td>Protein drugs produced <font color="blue">by recombinant</font> <font color="blue">technology</font>, even though they     have  the  <font color="blue">same primary amino acid sequence as</font> a <font color="blue">native human protein</font>,     <font color="blue">sometimes provoke formation</font> of <font color="blue">antibodies</font> that bind to the <font color="blue">protein drug</font></td>
    </tr>
    <tr>
      <td>Some such <font color="blue">antibodies</font> bind so as to prevent the <font color="blue">protein drug</font> from engaging     its  receptor,  and  <font color="blue">thus neutralize</font> the <font color="blue">drug activity</font> of the protein</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue"><font color="blue">neutralizing</font> <font color="blue">antibodies</font></font> provoked by <font color="blue">administration</font> of a protein     drug may react with <font color="blue">endogenous proteins</font> whose natural activity the drug was     intended to supplement, thereby inducing a total lack of <font color="blue">both <font color="blue">therapeutic</font></font>     and <font color="blue">natural <font color="blue">activities</font></font> in the patient</td>
    </tr>
    <tr>
      <td>We     will not know if the proteins we develop as product <font color="blue">candidates</font> will provoke     <font color="blue">neutralizing</font>  <font color="blue">antibody responses</font> in <font color="blue">humans until</font> they are evaluated in     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>It is possible that our product <font color="blue">candidates</font> may be rendered     in<font color="blue">effective</font> for the <font color="blue"><font color="blue">therapeutic</font> purpose</font> for which they are intended or could     <font color="blue">induce harm</font> to patients because of the <font color="blue">neutralizing</font> effect of <font color="blue">antibodies</font> to     <font color="blue">endogenous proteins</font> in humans in response to our proteins</td>
    </tr>
    <tr>
      <td>Additionally,  all  protein  drugs  expressed <font color="blue">by recombinant</font>     <font color="blue">technology</font> retain some trace of <font color="blue">contaminating proteins from</font> the host cells     used to express the <font color="blue">protein drug</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">host cell proteins may increase</font> the     chances of an <font color="blue">immunogenic response</font> that <font color="blue">could diminish</font> the <font color="blue">therapeutic</font>     efficacy of the protein</td>
    </tr>
    <tr>
      <td>Our GlycoAdvance <font color="blue">technology</font> enables the use of     <font color="blue">protein drug</font>s produced in <font color="blue">insect cells</font>, an <font color="blue"><font color="blue">expression system</font> which</font> has     <font color="blue">certain technical advantages</font> in enabling the <font color="blue">application</font> of our <font color="blue">technology</font>     to this protein, but for <font color="blue">which no product</font> to date has received marketing     <font color="blue">authorization</font>  in  the US or Europe</td>
    </tr>
    <tr>
      <td>It is possible that our product     <font color="blue">candidates</font> may be rendered in<font color="blue">effective</font> for the <font color="blue"><font color="blue">therapeutic</font> purpose</font> for which     they are intended because of the <font color="blue">neutralizing</font> effects of <font color="blue">antibodies</font> provoked     by  the  presence of <font color="blue">trace amounts</font> of <font color="blue">insect cell proteins</font> in our drug     <font color="blue">preparations</font></td>
    </tr>
    <tr>
      <td>We have limited product <font color="blue">development</font> and <font color="blue">commercial <font color="blue">manufacturing</font></font> experience,     and <font color="blue">face <font color="blue">challenges</font> unique</font> to proteins</td>
    </tr>
    <tr>
      <td>To  date, we have not <font color="blue">manufacture</font>d, <font color="blue">at <font color="blue">commercial scale</font></font>, any     <font color="blue">pharmaceutically active proteins nor</font> the enzymes, sugar <font color="blue">nucleotides</font> or other     reagents we use to <font color="blue">modify proteins</font></td>
    </tr>
    <tr>
      <td>We and the <font color="blue"><font color="blue">third parties</font> with whom</font> we contract to <font color="blue">manufacture</font> our     proteins face the <font color="blue">significant</font>, normal scale-up risks associated with protein     <font color="blue">manufacturing</font>: proteins are <font color="blue">difficult</font> to produce; it is <font color="blue">difficult</font> to scale     <font color="blue">up protein <font color="blue">manufacturing</font> processes</font>; and it is expensive to produce proteins</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face special risks</font> in <font color="blue">connection</font>                                        -14-       _________________________________________________________________           with  our <font color="blue">first product</font>, NE-180, an EPO protein</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success with</font> this     <font color="blue">program will depend on</font> our ability to have this protein <font color="blue">manufacture</font>d, at     <font color="blue">commercial scale</font>, in the <font color="blue">insect cell <font color="blue">expression system</font></font> (the production     source of NE-180), by a <font color="blue">collaborator</font> or supplier</td>
    </tr>
    <tr>
      <td>We do not know if we will     be able to locate a contract <font color="blue">manufacture</font>r outside of the US that will be     able to <font color="blue">manufacture</font> this protein <font color="blue">at <font color="blue">commercial scale</font></font> and <font color="blue">on economically</font>     <font color="blue">feasible terms</font></td>
    </tr>
    <tr>
      <td>To our knowledge, no <font color="blue">therapeutic</font> protein produced in this     <font color="blue">expression system</font> has yet received <font color="blue">marketing <font color="blue">authorization</font></font> in the US or     Europe,  which means that we <font color="blue">may face previously unidentified problems</font>     resulting from the use of this <font color="blue">expression system</font> and related <font color="blue">regulatory</font>     <font color="blue">challenges</font></td>
    </tr>
    <tr>
      <td>We will be <font color="blue">relying on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> the proteins,     enzymes,  sugar  <font color="blue">nucleotides</font>  and  other reagents we need to apply and     <font color="blue">commercialize</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">find parties willing</font>     and able to <font color="blue">manufacture</font> these <font color="blue">compounds at</font> acceptable prices, and we may     <font color="blue">become dependent on suppliers</font> that <font color="blue">could discontinue</font> our <font color="blue">supply arrangements</font>     or change <font color="blue">supply terms</font> to our <font color="blue">disadvantage</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our     ability to have these compounds <font color="blue">manufacture</font>d on a <font color="blue">commercial scale</font> or to     obtain <font color="blue">commercial quantities</font>, in either case, at <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>We may not     be able to <font color="blue">procure sufficient quantities</font> of the products we develop to meet     our needs for preclinical or clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">manufacturing</font> <font color="blue">facility</font> and <font color="blue"><font color="blue">manufacturing</font> process must adhere</font>     to the FDA‘s and/or other <font color="blue"><font color="blue">regulatory</font> agencies</font>’ evolving regulations on cGMP,     which are <font color="blue">enforced by</font> the FDA and others through <font color="blue">facilities</font> inspection     programs</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of products and <font color="blue">key reagents at</font> any <font color="blue">facility</font> will     be  subject  to  strict  quality  control, testing, and record keeping     <font color="blue">requirements</font>, and <font color="blue">continuing <font color="blue">obligations</font></font> regarding the submission of safety     reports and other post-market information</td>
    </tr>
    <tr>
      <td>Ultimately, we, our contract     <font color="blue">manufacture</font>rs, or other <font color="blue">suppliers may</font> not meet these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If  we  encounter  delays or <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">connection</font> with     <font color="blue">manufacturing</font>, <font color="blue">commercialization</font> of our products and <font color="blue">technologies</font> could be     delayed, we <font color="blue">could breach</font> our <font color="blue"><font color="blue">obligations</font> under</font> our <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>     and we could have <font color="blue">difficult</font>y obtaining <font color="blue"><font color="blue">necessary</font> financing</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> the success of our <font color="blue"><font color="blue">collaborative</font> relationships</font> and     the success of our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>We plan to rely to a large <font color="blue">extent on <font color="blue">collaborative</font> partners</font> to     co-develop  our  products and to <font color="blue">commercialize</font> products made using our     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> with Novo Nordisk,     BioGeneriX and MacroGenics</td>
    </tr>
    <tr>
      <td>We anticipate that <font color="blue">substantially</font> all of our     <font color="blue">revenues during</font> the <font color="blue">next several years will continue</font> to be <font color="blue">generated from</font>     <font color="blue">collaboration</font> or license <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">partnering strategy entails</font> many     risks, including:       •   we may be <font color="blue">unsuccessful</font> in <font color="blue">entering into</font> or maintaining <font color="blue">collaborative</font>     <font color="blue"><font color="blue">agreement</font>s</font> for the co-<font color="blue">development</font> of our products or the <font color="blue">commercialization</font>     of products <font color="blue">incorporating</font> our <font color="blue">technologies</font>;         •   we may not be successful in applying our <font color="blue">technologies</font> to the needs of     our <font color="blue">collaborative</font> partners;          •     our <font color="blue"><font color="blue">collaborator</font>s</font> may not be successful in, or may not remain     committed  to,  co-developing our products or <font color="blue">commercializing products</font>     <font color="blue">incorporating</font> our <font color="blue">technologies</font>;         •   our <font color="blue"><font color="blue">collaborator</font>s</font> may seek to develop other <font color="blue"><font color="blue">proprietary</font> <font color="blue">alternative</font>s</font>     to our products or <font color="blue">technologies</font>;         •   our <font color="blue"><font color="blue">collaborator</font>s</font> may not <font color="blue">commit sufficient resources</font> to <font color="blue">incorporating</font>     our <font color="blue">technologies</font> into their products;         •   our <font color="blue"><font color="blue">collaborator</font>s</font> are not obligated to market or <font color="blue">commercialize</font> our     products  or products <font color="blue">incorporating</font> our <font color="blue">technologies</font>, and they are not     required to achieve any specific <font color="blue">commercialization</font> schedule;         •   our <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> may be <font color="blue">terminated by</font> our <font color="blue">partners on</font>     short notice; and         •   <font color="blue">continued consolidation</font> in our <font color="blue">target markets may limit</font> our ability to     enter  into <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font>, or may result in <font color="blue"><font color="blue">termination</font>s</font> of     existing <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>-15-       _________________________________________________________________                     Given these risks, there is a great deal of <font color="blue">uncertainty</font> regarding     the success of our current and future <font color="blue">collaborative</font> efforts</td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product <font color="blue">liability</font></font> and related risks</td>
    </tr>
    <tr>
      <td>The use in humans of compounds developed by us or <font color="blue">incorporating</font>     our <font color="blue">technologies</font> may result in <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font>     claims can be expensive to defend, and may result in large <font color="blue">settlements</font> of     claims or <font color="blue">judgments against us</font></td>
    </tr>
    <tr>
      <td>Even if a <font color="blue">product <font color="blue">liability</font></font> claim is not     successful, the <font color="blue">adverse publicity</font>, time, and <font color="blue">expense involved</font> in defending     such a claim <font color="blue">may <font color="blue">interfere with</font></font> our business</td>
    </tr>
    <tr>
      <td>We may not be able to obtain     <font color="blue">insurance coverage at</font> a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to protect     <font color="blue">us against losses</font></td>
    </tr>
    <tr>
      <td>Risks Related to Intellectual Property       Blocking patents or claims of <font color="blue"><font color="blue">infringement</font> may stop</font> or delay the <font color="blue">development</font>     of our <font color="blue"><font color="blue">proprietary</font> products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success depends</font> in part on avoiding claims of     <font color="blue">infringement</font> of the patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have     devoted  <font color="blue">significant</font>  resources to <font color="blue">investigating</font> the <font color="blue">patent protection</font>     surrounding the proteins that are the subject of our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>The numerous patents, each with multiple claims, may be <font color="blue">difficult</font> to uncover     and interpret, leading to <font color="blue">uncertainty</font> about our freedom to operate</td>
    </tr>
    <tr>
      <td>It is     possible that we will not be aware of <font color="blue">issued patents</font> or <font color="blue">pending patent</font>     <font color="blue">application</font>s  that  are relevant to our product <font color="blue">candidates</font> because our     searches do not find them, or <font color="blue">pending patent</font> <font color="blue">application</font>s because they are     not  yet  publicly  available</td>
    </tr>
    <tr>
      <td>Our <font color="blue">interpretation</font> of <font color="blue">patents could</font> be     challenged, leading to <font color="blue">litigation</font>, and we could face claims of <font color="blue">infringement</font>     of rights of which we are unaware</td>
    </tr>
    <tr>
      <td>There  have  been  <font color="blue">significant</font>  <font color="blue">litigation</font>  and <font color="blue">interference</font>     <font color="blue">proceedings</font> regarding patent rights, and the patent situation regarding     particular  products is <font color="blue">often complex</font> and uncertain</td>
    </tr>
    <tr>
      <td>For example, with     respect to EPO, the target of our first <font color="blue">development</font> program, the status of     <font color="blue">issued patents</font> is currently being litigated by others and these patents     could  delay our ability to market a long-acting <font color="blue">EPO in the US As </font>we     <font color="blue">proceed with</font> this program and other targets, we may face <font color="blue">uncertainty</font> and     <font color="blue">litigation</font> could result, <font color="blue">which could lead</font> to <font color="blue">liability</font> for damages, prevent     our <font color="blue">development</font> and <font color="blue">commercialization</font> efforts, and <font color="blue">divert resources from</font> our     business strategy</td>
    </tr>
    <tr>
      <td>The cost of any <font color="blue">litigation</font> challenging our right to pursue our     <font color="blue">target proteins</font> or <font color="blue">technologies</font> could be substantial</td>
    </tr>
    <tr>
      <td>Others seeking to     develop next-generation versions of proteins, or the holders of <font color="blue">patents on</font>     our <font color="blue">target proteins</font>, may have <font color="blue">greater <font color="blue">financial resources</font></font>, making them     <font color="blue">better able</font> to bear the cost of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In particular, one company that     produces products that <font color="blue">will likely</font> be in <font color="blue">direct competition with</font> our current     product <font color="blue">candidates</font> has <font color="blue">aggressively defended</font> the patents related to its     products and this <font color="blue">could increase</font> the likelihood of <font color="blue">litigation</font> or the cost of     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of     patent <font color="blue">litigation</font> or other <font color="blue">proceedings</font> could have a material adverse effect     on our ability to develop, <font color="blue">manufacture</font>, and <font color="blue">market products</font>, form strategic     alliances, and compete in the marketplace</td>
    </tr>
    <tr>
      <td>Third parties from time to time may assert that we are infringing     their patents, trade secrets or know-how, although we believe our product     <font color="blue">candidates</font> do not infringe the products, trade secrets or know-how of third     parties</td>
    </tr>
    <tr>
      <td>In addition, patents may issue in the future to <font color="blue">third parties</font> that     our <font color="blue">technology</font> may infringe</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial costs in defending     ourselves and our <font color="blue">partners against</font> any such claims</td>
    </tr>
    <tr>
      <td>Furthermore, parties     making such claims may be able to obtain injunctive or other equitable     relief, which could <font color="blue">effective</font>ly block our ability or our partners’ ability     to  further  develop  or  <font color="blue">commercialize</font> some or all of our products or     <font color="blue">technologies</font>  in the US and abroad, and could result in the award of     substantial damages</td>
    </tr>
    <tr>
      <td>If we are found to infringe, we may be required to     obtain one or more licenses from <font color="blue">third parties</font> or be unable to proceed</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to obtain <font color="blue">such licenses at</font> a     <font color="blue">reasonable cost</font>, if at all</td>
    </tr>
    <tr>
      <td>Defense of any lawsuit or failure to obtain any     such required <font color="blue">license could</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>The failure to obtain, maintain or <font color="blue">protect patents</font> and other <font color="blue">intellectual</font>     <font color="blue">property could impact</font> our ability to compete <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>To  compete  <font color="blue">effective</font>ly,  we need to develop and maintain a     <font color="blue"><font color="blue">proprietary</font> position with</font> regard to our own <font color="blue">technologies</font>, products and     business</td>
    </tr>
    <tr>
      <td>We are seeking to develop <font color="blue">patent protection</font> for <font color="blue">therapeutic</font>     proteins that                                        -16-       _________________________________________________________________           include numerous claims for <font color="blue">composition</font> of matter, methods of use, and     methods of making</td>
    </tr>
    <tr>
      <td>Legal standards relating to the validity and scope of     claims in our <font color="blue">technology</font> field are <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>Therefore, the degree of     future protection in the US and other countries for our <font color="blue"><font color="blue">proprietary</font> rights</font>     in our core <font color="blue">technologies</font> and products made using these <font color="blue">technologies</font> is also     uncertain</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> that we <font color="blue">face with respect</font> to our     patents and other <font color="blue"><font color="blue">proprietary</font> rights</font> include the following:       •   the <font color="blue">pending patent</font> <font color="blue">application</font>s we have filed, or to which we have     exclusive rights, may not result in <font color="blue">issued patents</font>, or may take <font color="blue">longer than</font>     we expect to result in <font color="blue">issued patents</font>;         •   we may be subject to <font color="blue">interference</font> <font color="blue">proceedings</font>;         •   we may be subject to opposition <font color="blue">proceedings</font> in <font color="blue">foreign countries</font>;         •   the claims of any patents that are <font color="blue">issued may</font> not provide meaningful     protection;         •   we may not be able to develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that     are patentable;         •   the <font color="blue">patents licensed</font> or issued to us or our customers may not provide     a <font color="blue">competitive advantage</font>;         •   other companies may challenge <font color="blue">patents licensed</font> or issued to us or our     customers;         •   other <font color="blue">companies may independently</font> develop similar or <font color="blue">alternative</font>     <font color="blue">technologies</font>, or duplicate our <font color="blue">technologies</font>;         •   other companies may design around <font color="blue">technologies</font> we have licensed or     developed; and         •   <font color="blue">enforcement</font> of patents is complex, uncertain and expensive</td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">patents will</font> be issued as a result of     any of our pending <font color="blue">application</font>s, and we cannot be certain that any of our     <font color="blue">issued patents</font> will give us adequate protection from competing products</td>
    </tr>
    <tr>
      <td>For     example, <font color="blue">issued patents</font> may be <font color="blue">circumvented</font> or challenged, declared invalid     or unenforceable, or narrowed in scope</td>
    </tr>
    <tr>
      <td>In addition, since publication of     <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature often lags behind actual</font>     <font color="blue">discoveries</font>,  we  cannot be certain that we were the first to make our     <font color="blue">inventions</font> or to file patent <font color="blue">application</font>s covering those <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In the     event that another party has also filed a patent <font color="blue">application</font> relating to an     invention  claimed  by  us,  we  may  be required to <font color="blue">participate</font> in an     <font color="blue">interference</font> proceeding declared by the US Patent and Trademark Office to     determine  priority  of  invention,  which could result in substantial     <font color="blue">uncertainties</font> and costs for us, even if the eventual outcome were favorable     to us</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that <font color="blue">others may</font> obtain <font color="blue">issued patents</font> that could     prevent  us  <font color="blue">from commercializing</font> our products or require us to obtain     licenses requiring the payment of <font color="blue">significant</font> fees or royalties in order to     enable  us  to  conduct our business</td>
    </tr>
    <tr>
      <td>As to those patents that we have     licensed, our rights depend on maintaining our <font color="blue">obligations</font> to the licensor     under the applicable license <font color="blue">agreement</font>, and we may be unable to do so</td>
    </tr>
    <tr>
      <td>Furthermore,  patent  <font color="blue">protection available</font> to <font color="blue">us may vary</font> in <font color="blue">different</font>     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>In particular, the laws in some <font color="blue">countries provide</font> little     <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>The  cost to us of any patent <font color="blue">litigation</font> or other proceeding     relating to our patents or <font color="blue">application</font>s, even if resolved in our favor,     could be substantial</td>
    </tr>
    <tr>
      <td>Our ability to enforce our <font color="blue">patent protection</font> could be     limited by our <font color="blue">financial resources</font>, and may be subject to <font color="blue">lengthy delays</font></td>
    </tr>
    <tr>
      <td>If     we are unable to <font color="blue">effective</font>ly enforce our <font color="blue"><font color="blue">proprietary</font> rights</font>, or if we are     found to infringe the rights of others, we may be in breach of our license     <font color="blue"><font color="blue">agreement</font>s</font> with our partners</td>
    </tr>
    <tr>
      <td>In addition to patents and patent <font color="blue">application</font>s, we <font color="blue">depend upon</font>     trade  secrets  and  <font color="blue">proprietary</font>  know-how  to protect our <font color="blue">proprietary</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We  require  our  employees,  <font color="blue">consultants</font>,  advisors, and     <font color="blue"><font color="blue">collaborator</font>s</font> to enter into <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> that prohibit the     <font color="blue">disclosure</font> of <font color="blue">confidential</font> information to any other parties</td>
    </tr>
    <tr>
      <td>We require our     employees  and  <font color="blue">consultants</font>  to disclose and assign to us their ideas,     <font color="blue">development</font>s,  <font color="blue">discoveries</font>,  and <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> may not,     however, provide adequate protection for our trade secrets, know-how, or     other  <font color="blue">proprietary</font> information in the event of any <font color="blue">unauthorized use</font> or     <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>-17-       _________________________________________________________________           We may have to develop or license <font color="blue">alternative</font> <font color="blue">technologies</font> if we are unable     to maintain or obtain key <font color="blue">technology</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">licensed patents</font> and patent <font color="blue">application</font>s from a number of     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">proprietary</font> rights</font> have been licensed to us under     <font color="blue"><font color="blue">agreement</font>s</font> that have performance <font color="blue">requirements</font> or other <font color="blue">contingencies</font></td>
    </tr>
    <tr>
      <td>The     failure  to  <font color="blue">comply with</font> these <font color="blue">provisions could lead</font> to <font color="blue">termination</font> or     <font color="blue">modifications</font> of our rights to these licenses</td>
    </tr>
    <tr>
      <td>Additionally, we may need to     obtain <font color="blue"><font color="blue">additional</font> licenses</font> to patents or other <font color="blue"><font color="blue">proprietary</font> rights</font> from other     parties to facilitate <font color="blue">development</font> of our <font color="blue">proprietary</font> <font color="blue">technology</font> base</td>
    </tr>
    <tr>
      <td>The     ownership of <font color="blue">patents exclusively licensed</font> to us may be subject to challenge     if <font color="blue">inventorship</font> was not <font color="blue">adequately investigated</font> and represented</td>
    </tr>
    <tr>
      <td>If our     existing  licenses  are  terminated or if we are unable to obtain such     <font color="blue"><font color="blue">additional</font> licenses</font> on acceptable terms, our ability to perform our own     research  and <font color="blue">development</font> and to <font color="blue">comply with</font> our <font color="blue"><font color="blue">obligations</font> under</font> our     <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> may be <font color="blue">delayed while</font> we seek to develop or license     <font color="blue">alternative</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Risks Related to Competition       Our <font color="blue"><font color="blue">competitors</font> may</font> develop better or more <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">characterized by</font> extensive <font color="blue">research efforts</font> and     rapid  <font color="blue">technological</font>  progress</td>
    </tr>
    <tr>
      <td>New <font color="blue">development</font>s in <font color="blue">molecular biology</font>,     <font color="blue">medicinal <font color="blue">chemistry</font></font> and other fields of biology and <font color="blue">chemistry</font> are expected     to <font color="blue">continue at</font> a rapid pace in <font color="blue">both industry</font> and academia</td>
    </tr>
    <tr>
      <td>Our potential     <font color="blue">competitors</font> include both public and <font color="blue">private pharmaceutical</font> and bio<font color="blue">technology</font>     companies, as well as academic <font color="blue">institutions</font>, <font color="blue">government</font>al agencies and other     public and <font color="blue">private research <font color="blue">organizations</font></font> that are <font color="blue">also conducting research</font>     <font color="blue">activities</font> and seeking <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>A number of these <font color="blue">competitors</font> are working on the <font color="blue">development</font> of     next-generation protein <font color="blue">therapeutic</font>s</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitors</font> include     Maxygen, Nektar Therapeutics, BioRexis, Human Genome Sciences and Alkermes</td>
    </tr>
    <tr>
      <td>Other companies have <font color="blue">programs focused on</font> developing next-generation or     improved versions of EPO and G-CSF, and some are already marketing improved     versions of these products</td>
    </tr>
    <tr>
      <td>Other companies are active in this     area, and we expect that <font color="blue">competition will increase</font></td>
    </tr>
    <tr>
      <td>We are also aware that     there are <font color="blue">several companies</font> engaged in <font color="blue">glycobiology research</font></td>
    </tr>
    <tr>
      <td>In  addition,  we <font color="blue">may compete with companies commercializing</font>     first-generation protein <font color="blue">therapeutic</font>s, as a result of <font color="blue">pricing practices</font> or     <font color="blue"><font color="blue">reimbursement</font> limitations</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in developing and marketing     products that have <font color="blue">significant</font> advantages over first-generation products, if     first-generation products are <font color="blue">available at</font> a lower out-of-pocket cost to the     consumer, health-care providers and consumers may choose first-generation     <font color="blue">products instead</font> of next-generation versions</td>
    </tr>
    <tr>
      <td>Compared to us, many of our likely and potential <font color="blue">competitors</font> have     more:       •   financial, scientific and technical resources;         •   product <font color="blue">development</font>, <font color="blue">manufacturing</font> and marketing <font color="blue">capabilities</font>;         •   experience conducting pre<font color="blue">clinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> of new     products; and         •   experience in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for products</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may succeed in developing products and <font color="blue">technologies</font>     that are more <font color="blue">effective</font> or <font color="blue">less costly than ours</font> and that would render our     products or <font color="blue">technologies</font>, or both, obsolete or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>We know that     other <font color="blue">companies with</font> substantial resources are working on the <font color="blue">development</font> of     next-generation  proteins,  and  they  may  achieve  better results in     <font color="blue">enzymatically modifying</font> our <font color="blue">target proteins</font> or the <font color="blue">target proteins</font> of our     potential <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">also may prove</font> to be more successful in designing,     <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>If we are successful in developing our     own <font color="blue">drug <font color="blue">candidates</font></font> or versions of drugs that are <font color="blue">no longer patented</font>, we     <font color="blue">will compete with</font> other drug <font color="blue">manufacture</font>rs for market share</td>
    </tr>
    <tr>
      <td>If we are     unable  to  compete <font color="blue">successfully</font>, our commercial <font color="blue">opportunities</font> will be     diminished</td>
    </tr>
    <tr>
      <td>-18-       _________________________________________________________________                     In addition, while there is no proven <font color="blue">abbreviated</font> <font color="blue">regulatory</font>     pathway for follow-on biologics, this <font color="blue">possibility</font> is under discussion in the     US and other <font color="blue">jurisdictions</font> and has <font color="blue">been adopted</font> in part in Europe</td>
    </tr>
    <tr>
      <td>If an     <font color="blue">abbreviated</font> <font color="blue">regulatory</font> process is adopted for the approval of follow-on     biologics  in  any major market, competition <font color="blue">could increase</font> in related     segments of the <font color="blue">therapeutic</font> protein market</td>
    </tr>
    <tr>
      <td>We may be unable to retain <font color="blue">key employees</font> or <font color="blue">recruit <font color="blue">additional</font> qualified</font>     personnel</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">specialized scientific</font> nature of our business, we     are highly <font color="blue">dependent upon</font> qualified scientific, technical and managerial     personnel, including our research and <font color="blue">development</font> team</td>
    </tr>
    <tr>
      <td>The <font color="blue">advancement</font> of     our business is <font color="blue">dependent upon</font> our management team‘s ability to evaluate     <font color="blue">collaboration</font> <font color="blue">opportunities</font> and on their ability to focus our company’s     efforts</td>
    </tr>
    <tr>
      <td>Our anticipated research and <font color="blue">development</font> efforts will require     <font color="blue">additional</font> expertise and the addition of new <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>There is intense competition for <font color="blue">qualified management</font> and research     and <font color="blue">development</font> personnel in the <font color="blue">pharmaceutical field</font></td>
    </tr>
    <tr>
      <td>Therefore, we may not     be able to attract and retain the <font color="blue">qualified personnel</font> <font color="blue">necessary</font> for our     business</td>
    </tr>
    <tr>
      <td>The loss of the services of existing personnel, as well as the     failure to recruit <font color="blue">additional</font> key scientific, technical and managerial     personnel  in a timely manner, could harm our research and <font color="blue">development</font>     programs  and  our  ability  to  manage day-to-day <font color="blue">operations</font>, attract     <font color="blue">collaboration</font> partners, attract and retain other employees, and generate     revenues</td>
    </tr>
    <tr>
      <td>We do not maintain “key person” <font color="blue">life insurance on</font> any of our     employees</td>
    </tr>
    <tr>
      <td>Risks Related to Government Regulation       We  are  subject  to  extensive  <font color="blue">government</font>  regulation, and we or our     <font color="blue"><font color="blue">collaborator</font>s</font> may not obtain <font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> or <font color="blue">may encounter</font>     <font color="blue">long delays</font> and large <font color="blue">expenditures</font> in obtaining <font color="blue">such approvals</font></td>
    </tr>
    <tr>
      <td>The research, <font color="blue">development</font>, <font color="blue">manufacture</font> and control, marketing, and     sale  of  our  reagents  and product <font color="blue">candidates</font> <font color="blue">manufacture</font>d using our     <font color="blue">technologies</font> are subject to <font color="blue">significant</font>, but varying, degrees of regulation     by a number of <font color="blue">government</font> <font color="blue">authorities</font> in the US and other countries</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical  </font>product  <font color="blue">candidates</font>  <font color="blue">manufacture</font>d  using our     <font color="blue">technologies</font> must undergo an extensive <font color="blue"><font color="blue">regulatory</font> approval</font> process before     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>This process is <font color="blue">regulated by</font> the FDA and by comparable     agencies <font color="blue">in Europe </font>and in other countries</td>
    </tr>
    <tr>
      <td>The US and foreign <font color="blue">regulatory</font>     agencies have substantial <font color="blue">discretion</font> to terminate <font color="blue"><font color="blue">clinical trial</font>s</font>, require     <font color="blue">additional</font> testing, delay or withhold <font color="blue">registration</font> and marketing approval,     and mandate product <font color="blue">withdrawals</font></td>
    </tr>
    <tr>
      <td>In addition, the US or other <font color="blue"><font color="blue">regulatory</font> agencies</font> could, at any     time in the <font color="blue"><font color="blue">regulatory</font> approval</font> process, place the <font color="blue">regulatory</font> submission for     a <font color="blue">product candidate</font> on “hold” pending the receipt, review and approval of     <font color="blue">additional</font> information</td>
    </tr>
    <tr>
      <td>The IND for our first <font color="blue">product candidate</font>, NE-180, is     <font color="blue">currently on</font> hold in the US There is the risk that we will not be taken     off hold and <font color="blue">will therefore</font> be unable to <font color="blue">proceed with</font> <font color="blue"><font color="blue">clinical trial</font>s</font> of     NE-180 in the US               We  and our <font color="blue"><font color="blue">collaborator</font>s</font> intend to base our <font color="blue">submissions</font> for     <font color="blue"><font color="blue">regulatory</font> approval</font> and the information contained in such <font color="blue">submissions</font> on our     understanding of the <font color="blue">requirements</font> of the FDA and its foreign <font color="blue">counterparts</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> information is required, we <font color="blue">may face delays</font> and <font color="blue">additional</font>     costs</td>
    </tr>
    <tr>
      <td>The <font color="blue">specific risks</font> of <font color="blue">protein drug</font>s may result in the <font color="blue">application</font>     of more stringent <font color="blue">regulatory</font> <font color="blue">requirements</font> prior to approval of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We face special <font color="blue">challenges</font> in <font color="blue">connection</font> with the <font color="blue">development</font> of     proteins produced in the <font color="blue">insect cell <font color="blue">expression system</font></font></td>
    </tr>
    <tr>
      <td>To our knowledge, no     <font color="blue">therapeutic</font> protein for human use produced in this <font color="blue">expression system</font> has     <font color="blue">been submitted</font> for <font color="blue">marketing <font color="blue">authorization</font></font> in the US or Europe, and we may     encounter <font color="blue">long delays</font> and large <font color="blue">expenditures</font> or other <font color="blue">regulatory</font> hurdles in     <font color="blue">connection</font>  with  the  <font color="blue">approval process</font> for a product produced in this     <font color="blue">expression system</font></td>
    </tr>
    <tr>
      <td><font color="blue">Neither  </font>we nor our <font color="blue"><font color="blue">collaborator</font>s</font> have submitted any product     <font color="blue">candidates</font> <font color="blue">incorporating</font> our <font color="blue">technologies</font> for approval to the FDA or any     other <font color="blue">regulatory</font> authority</td>
    </tr>
    <tr>
      <td>If any <font color="blue">product candidate</font> <font color="blue">manufacture</font>d using our     <font color="blue">technology</font> is submitted for <font color="blue"><font color="blue">regulatory</font> approval</font>, it may not receive the     approvals <font color="blue">necessary</font> for <font color="blue">commercialization</font>, the desired labeling claims, or     adequate levels of <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Any delay in receiving, or failure to     receive, these approvals                                        -19-       _________________________________________________________________           would  <font color="blue">adversely</font>  affect  our  ability to <font color="blue">generate product revenues</font> or     royalties, and we will have already spent <font color="blue">significant</font> sums in pursuing     approval</td>
    </tr>
    <tr>
      <td>We  anticipate  that  the <font color="blue">development</font> of our next-generation     <font color="blue">proprietary</font>  proteins  <font color="blue">will involve</font> a traditional <font color="blue">development</font> program,     including <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Any new <font color="blue">government</font>al regulations may delay or     alter <font color="blue"><font color="blue">regulatory</font> approval</font> of any <font color="blue">product candidate</font> <font color="blue">manufacture</font>d using our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If an <font color="blue">abbreviated</font> <font color="blue">regulatory</font> process is adopted for the approval     of follow-on biologics in any major market, competition <font color="blue">could increase</font> in     related segments of the <font color="blue">therapeutic</font> protein market</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the     impact  of  adverse  <font color="blue">government</font>al  action that might arise <font color="blue">from future</font>     <font color="blue">legislative</font> and <font color="blue">administrative action</font></td>
    </tr>
    <tr>
      <td>Even  if we or our <font color="blue"><font color="blue">collaborator</font>s</font> are successful in obtaining     <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for any of our products, our or their <font color="blue">manufacturing</font>     processes  will  be  subject  to <font color="blue">continued review by</font> the FDA and other     <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">later discovery</font> of <font color="blue">unknown problems with</font> our     products,  products  <font color="blue">incorporating</font>  our <font color="blue">technologies</font>, or <font color="blue">manufacturing</font>     processes could result in <font color="blue">restrictions on such products</font> or <font color="blue">manufacturing</font>     processes, including <font color="blue">potential withdrawal</font> of the <font color="blue">products from</font> the market</td>
    </tr>
    <tr>
      <td>In  addition,  if  <font color="blue">regulatory</font>  <font color="blue">authorities</font>  determine  that  we or our     <font color="blue"><font color="blue">collaborator</font>s</font>  have  not <font color="blue">complied with regulations</font> in the research and     <font color="blue">development</font> of a <font color="blue">product candidate</font> or the <font color="blue">manufacture</font> and control of our     reagents, then we or our <font color="blue"><font color="blue">collaborator</font>s</font> may not obtain <font color="blue">necessary</font> approvals to     market and sell the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">reimbursement</font> for our <font color="blue"><font color="blue">collaborator</font>s</font>’ or our <font color="blue">future product</font>     <font color="blue">candidates</font> may not be adequate</td>
    </tr>
    <tr>
      <td>Even  if <font color="blue"><font color="blue">regulatory</font> approval</font> is obtained to sell any product     <font color="blue">candidates</font>   <font color="blue">incorporating</font>  our  <font color="blue">technologies</font>,  our  future  revenues,     <font color="blue">profitability</font>, and access to <font color="blue">capital will</font> be determined in part by the price     at  which  we  or  our <font color="blue"><font color="blue">collaborator</font>s</font> can <font color="blue">sell such products</font></td>
    </tr>
    <tr>
      <td>There are     continuing efforts by <font color="blue">government</font>al and private third-party payors to contain     or reduce the costs of <font color="blue">health care through various</font> means</td>
    </tr>
    <tr>
      <td>We expect a number     of  federal, state, and <font color="blue">foreign proposals</font> to control the cost of drugs     through <font color="blue">government</font>al regulation</td>
    </tr>
    <tr>
      <td>We are unsure of the form that any health     <font color="blue">care reform legislation may</font> take or what <font color="blue">actions federal</font>, state, foreign,     and <font color="blue">private payors may</font> take in response to the <font color="blue">proposed reforms</font></td>
    </tr>
    <tr>
      <td>Therefore,     we <font color="blue">cannot predict</font> the effect of any <font color="blue">implemented reform on</font> our business</td>
    </tr>
    <tr>
      <td>Our and our <font color="blue"><font color="blue">collaborator</font>s</font>’ ability to <font color="blue">commercialize</font> our products     <font color="blue">successfully</font> will depend, in part, on the extent to which <font color="blue">reimbursement</font> for     the cost of such products and related <font color="blue">treatments</font> will be available from     <font color="blue">government</font> health <font color="blue">administration</font> <font color="blue">authorities</font>, such as Medicare and Medicaid     in the US, <font color="blue">private health insurers</font>, and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font><font color="blue">uncertainty</font>  exists  as  to the <font color="blue">reimbursement</font> status of <font color="blue">newly approved</font>     <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party coverage may not be available to     <font color="blue">enable us</font> to maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font>     return  on  <font color="blue">investment</font> in <font color="blue">product research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inadequate     </font>coverage and <font color="blue">reimbursement</font> levels provided by <font color="blue">government</font> and third-party     payors  for  use of our or our <font color="blue"><font color="blue">collaborator</font>s</font>’ products may cause these     products to fail to achieve <font color="blue">market acceptance</font> and would cause us to lose     anticipated revenues and <font color="blue">delay achievement</font> of <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>It is possible     that  <font color="blue">reimbursement</font>  may  be  limited  to  that which is available for     first-generation  versions of one or more of our or our <font color="blue">collaborator</font>’s     products,  making it harder for us and our <font color="blue"><font color="blue">collaborator</font>s</font> to realize an     <font color="blue">appropriate</font> return</td>
    </tr>
    <tr>
      <td>Risks Related to Facilities, Business Interruption, and the Environment       The  use  of  <font color="blue">hazardous</font>  materials in our <font color="blue">operations</font> may subject us to     <font color="blue">environmental</font> claims or <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> processes involve the <font color="blue">controlled use</font>     of <font color="blue">hazardous</font> materials, chemicals, and <font color="blue"><font color="blue">radioactive</font> compounds</font></td>
    </tr>
    <tr>
      <td>We conduct     <font color="blue">experiments</font> that are <font color="blue">quite common</font> in the bio<font color="blue">technology</font> industry, in which we     use small quantities of corrosive, toxic and <font color="blue">flammable chemicals</font>, and trace     amounts  of  <font color="blue">radioactive</font>  materials</td>
    </tr>
    <tr>
      <td>The risk of <font color="blue"><font color="blue">accident</font>al injury</font> or     <font color="blue">contamination from</font> these <font color="blue">materials cannot</font> be <font color="blue">entirely eliminated</font></td>
    </tr>
    <tr>
      <td>We do not     maintain a <font color="blue">separate insurance policy</font> for these types of risks</td>
    </tr>
    <tr>
      <td>In the event     of an <font color="blue">accident</font> or <font color="blue">environmental</font> discharge, we may be held liable for any     resulting damages, and any <font color="blue">liability</font> could exceed our resources</td>
    </tr>
    <tr>
      <td>We are     subject to federal, state, and <font color="blue">local laws</font> and <font color="blue">regulations governing</font> the use,     storage, handling, and disposal of these materials and <font color="blue">specified waste</font>     products</td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">compliance with</font> these laws and <font color="blue">regulations could</font> be     <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>-20-       _________________________________________________________________           <font color="blue">Destructive </font><font color="blue">actions <font color="blue">by activist</font>s</font> or <font color="blue"><font color="blue">terrorists</font> could damage</font> our <font color="blue">facilities</font>,     <font color="blue">interfere with</font> our research <font color="blue">activities</font>, and cause <font color="blue">ecological harm</font></td>
    </tr>
    <tr>
      <td><font color="blue">Activists </font>and <font color="blue">terrorists</font> have shown a <font color="blue">willingness</font> to injure people     and  damage physical <font color="blue">facilities</font>, equipment and <font color="blue">biological materials</font> to     publicize  or  otherwise  further their <font color="blue">ideological</font> causes</td>
    </tr>
    <tr>
      <td>Our or our     <font color="blue"><font color="blue">collaborator</font>s</font>’ <font color="blue">operations</font> and research <font color="blue">activities</font>, and services conducted     for us by <font color="blue">third parties</font>, could be <font color="blue">adversely</font> affected by such acts</td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">damage could delay</font> our research projects and decrease our ability to conduct     <font color="blue">future research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Damage caused <font color="blue">by activist</font> or terrorist     <font color="blue">incidents could also</font> cause the release of <font color="blue">hazardous</font> materials, including     chemicals, <font color="blue">radioactive</font> and <font color="blue">biological materials</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue">significant</font>  <font color="blue">interruption</font> to our ability to conduct our     business <font color="blue">operations</font>, research and <font color="blue">development</font> <font color="blue">activities</font>, or <font color="blue">manufacturing</font>     <font color="blue">operations</font> could reduce our revenue and increase our expenses</td>
    </tr>
    <tr>
      <td>Risk Related to Stock Market       Our stock price <font color="blue">may continue</font> to experience <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> of securities of thinly-traded bio<font color="blue">technology</font>     <font color="blue">companies such as ours generally</font> are <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>For example, since     March 1, 2005, the price of our <font color="blue">common stock</font> reached a high of dlra4dtta49 per     share in July 2005 and a low of dlra1dtta70 per share in November 2005</td>
    </tr>
    <tr>
      <td>In this <font color="blue">market environment</font>, the sale of a substantial number of     shares of our <font color="blue">common stock</font> in the <font color="blue">public market</font> or the <font color="blue">perception</font> that such     a sale might occur <font color="blue">would likely</font> have an adverse effect on the <font color="blue">market price</font>     of  our <font color="blue">common stock</font>, at least for the short term</td>
    </tr>
    <tr>
      <td>We have a number of     investors who hold <font color="blue">relatively</font> large positions in our securities</td>
    </tr>
    <tr>
      <td>A decision     by any of these investors to sell all or a block of their holdings of our     <font color="blue">common stock</font> could cause our stock price to drop <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>The <font color="blue">market also continues</font> to experience <font color="blue">significant</font> price and     volume  <font color="blue">fluctuations</font>,  some  of  which  are unrelated to the operating     performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the price of our     <font color="blue">common stock</font> has fluctuated <font color="blue">significant</font>ly and <font color="blue">may continue</font> to do so in the     future</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors could</font> have a <font color="blue">significant</font> effect on the <font color="blue">market price</font> for     our <font color="blue">common stock</font>, including:         •   preclinical and <font color="blue">clinical trial</font> results;         •   product <font color="blue">development</font> delays;         •   <font color="blue">regulatory</font> delays;         •   an <font color="blue">announcement</font> or <font color="blue">termination</font> of a <font color="blue">collaborative</font> relationship by us     or any of our partners or <font color="blue">competitors</font>;         •   <font color="blue">development</font>s relating to our <font color="blue">patent position</font> or other <font color="blue">proprietary</font>     rights;          •     <font color="blue">announcement</font>s of <font color="blue">technological</font> innovations or new <font color="blue">therapeutic</font>     products;         •   <font color="blue">government</font> regulations;         •   public concern as to the safety of products developed by us or others;     and         •   <font color="blue">general market conditions</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> brought against us as a result of this <font color="blue">volatility</font>     could  result in substantial costs and a diversion of our management’s     attention  and  resources, which could <font color="blue">negatively impact</font> our financial     condition, revenues, results of <font color="blue">operations</font>, and the price of our common     stock</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> capital</font> by issuing <font color="blue">equity securities</font> in a     <font color="blue">fluctuating market</font>, many or all of our <font color="blue">existing stockholders may</font> experience     substantial dilution, and if we need to <font color="blue">raise capital by issuing equity</font>     <font color="blue">securities at</font> a time                                        -21-       _________________________________________________________________           when our stock price is down, we may have <font color="blue">difficult</font>y raising sufficient     capital to meet our <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">risks described</font> in these     “RISK FACTORS” occurred, of if any <font color="blue">unforeseen risk affected</font> our performance,     it could have a dramatic and <font color="blue">adverse impact on</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  have <font color="blue">entered into</font> some <font color="blue"><font color="blue">agreement</font>s</font> denominated, wholly or     partly, in Euros or other foreign currencies, and, in the future, we may     enter  into  <font color="blue">additional</font>, <font color="blue">significant</font> <font color="blue"><font color="blue">agreement</font>s</font> denominated in foreign     currencies</td>
    </tr>
    <tr>
      <td>To date, we have not <font color="blue">entered into</font> any contracts to     reduce the risk of <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates</font></td>
    </tr>
    <tr>
      <td>In the future,     depending upon the amounts payable under any such <font color="blue"><font color="blue">agreement</font>s</font>, we may enter     into forward foreign exchange contracts to reduce the risk of unpredictable     changes in these costs</td>
    </tr>
    <tr>
      <td>However, due to the <font color="blue">variability</font> of timing and amount     of <font color="blue">payments under</font> any such <font color="blue"><font color="blue">agreement</font>s</font>, foreign exchange contracts may not     mitigate the potential <font color="blue">adverse impact on</font> our financial results</td>
    </tr>
  </tbody>
</table>